Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annu... ( SAN DIEGO Oct. 31 /- Optimer Pharmace...)

HOME >> BIOLOGY >> TECHNOLOGY

Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting

Date:10/31/2009

SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish General Hospital in Montreal, Quebec, Canada, presented results showing that fidaxomicin is associated with faster resolution of diarrhea. In patients with more pronounced diarrhea (ie. not resolving in the first 24 hours of therapy), fidaxomicin was associated with a faster time to resolution of diarrhea than vancomycin (79 hours vs. 105 hours, p=0.056). It is possible that decreasing the duration of diarrhea may have a direct impact on reducing the spread of CDI in healthcare facilities and lowering overall environmental spore contamination, thereby decreasing CDI rates and leading to earlier discharge of CDI patients from the hospital.

In another presentation, Kathleen M. Mullane, D.O., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented data that indicated fidaxomicin may be a more effective therapy for CDI in patients requiring concomitant antibiotics. Treatment of CDI is often complicated by systemic infections requiring concomitant antibiotics. The analysis indicated that in patients receiving concomitant antibiotics, those treated with fidaxomicin versus vancomycin, had a significantly improved global cure rate
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
3. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
4. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
5. AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually
6. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
7. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
8. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
9. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
10. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
11. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients

Post Your Comments:

Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annu...( SAN DIEGO Oct. 31 /- Optimer Pharmace...)